Dermacyte® Liquid for Treatment of Cutaneous Ulcers and Wounds
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
The objective of this study is to make Dermacyte Liquid available on an expanded access basis to treat cutaneous ulcers and wounds refractory to initial treatment or that do not have adequate alternative treatments. Minimal data will be collected to evaluate the efficacy and safety of Dermacyte Liquid.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 6, 2024
CompletedFirst Posted
Study publicly available on registry
December 12, 2024
CompletedFebruary 25, 2025
February 1, 2025
December 6, 2024
February 21, 2025
Conditions
Interventions
Repeat dose subcutaneous drug injection for the treatment of serious chronic wounds.
Eligibility Criteria
You may qualify if:
- Must be 18 years of age or older
- Must have a cutaneous ulcer or wound refractory to initial treatment or does not have an adequate treatment alternative, as determined by the Investigator
You may not qualify if:
- Must not be pregnant or lactating
- Must not have known malignancies
- Must not be less than 18 years of age
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The WISH Clinic
Arvada, Colorado, 80004, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 6, 2024
First Posted
December 12, 2024
Last Updated
February 25, 2025
Record last verified: 2025-02